What is Pyxis Oncology Inc?
, a clinical stage company, engages in the development of therapeutics to treat solid tumors.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 188.98M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.